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Abstract
Background: Metabolic syndrome (MetS) is a constellation of symptoms used as a measure to identify patients
at increased risk for cardiovascular disease, type 2 diabetes, and all-cause mortality. The results of prolonged life
expectancy and cumulative toxic effects of antiretroviral therapy increase the chance that HIV can cause clinical
abnormalities, including MetS.
Methods: We evaluated 89 people living with HIV (PLWH; mean age 48 ± 7 years; mean duration of HIV infection
17 ± 12 years; 47% men; 66% African-American, 22% Hispanic, and 10% non-Hispanic white; and 84% unemployed)
enrolled in a community-based exercise training and nutrition education program targeting individuals of low
socio-economic status (SES). The prevalence of MetS characteristics and the factors associated with the presence of
MetS were analyzed.
Results: One in three (33%; 12 men and 17 women) PLWH met ATPIII criteria for MetS. In our cohort, MetS was
driven by high waist circumference and elevated blood pressure. In addition, higher use of protease inhibitors,
elevated hemoglobin A1c (HbA1c), greater self-reported daily caloric intake and consumption of carbohydrates,
sugar, added sugar, and higher glycemic load were found among the individuals with MetS, compared to those
without it. Elevated HbA1c and high total sugar consumption were the strongest predictors and accounted for
30% of the occurrence of MetS.
Conclusions: The overall prevalence of MetS in our PLWH cohort receiving antiretroviral therapy is higher than
previously reported in the general population and in other PLWH cohorts. Additional work is needed to determine
whether MetS is a more disease dependent or lifestyle dependent condition in PLWH.
Keywords: HIV, Metabolic syndrome, HbA1c, Sugar consumption, Low SES
Background
Metabolic syndrome (MetS) is a condition characterized
by the clustering of well-documented cardiovascular
disease (CVD) risk factors with various underlying path-
ologies. According to the National Cholesterol Education
Program/Adult Treatment Panel III (NCEPATPIII) criteria,
MetS is defined by three or more of the following features:
abdominal obesity, hypertriglyceridemia, low levels of high-
density lipoprotein cholesterol (HDL-C), insulin resistance,
and hypertension [1]. MetS comprises risk factors inde-
pendently associated with type 2 diabetes and CVD [2].
Identifying individuals with MetS and implementing thera-
peutic lifestyle changes along with medications may halt
the progression of these chronic diseases. According to the
latest report utilizing the National Health and Nutrition
Examination Survey (NHANES), the prevalence of MetS
among US adults was 23% [3].
The success of antiretroviral therapy (ART) has led to
a decline in morbidity and mortality in people living
with HIV (PLWH) [4]. As a result of efficacious and
more accessible treatment, HIV has become a manageable
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chronic disease. However, prolonged life expectancy with
HIV, accompanied with sustained toxic exposure to ART,
can cause clinically relevant abnormalities, including the
features of MetS [5]. Studies report different rates and
predominant characteristics of MetS in PLWH, compared
to the healthy population. Most studies have found a
prevalence of 11% to 26% in PLWH, with this population’s
rate being comparable or slightly lower than in the general
US population [4,6-9]. Conversely, a few older Italian
studies have reported higher rates in PLWH, ranging from
33% to 45% [10-12]. In terms of MetS criteria, most
commonly, PLWH have hypertriglyceridemia and low
HDL-C levels, compared to abdominal obesity, low HDL-
C levels, and hypertension in the general US population
[13]. Similar to general health care guidelines, HIV treat-
ment guidelines recommend screening patients for MetS
to reduce the risk for CVD morbidity and mortality. Thus,
the purpose of this study was to evaluate and report: (1)
the prevalence of MetS and each of its five characteristics
and (2) factors associated with the presence of MetS in
PLWH receiving stable ART and who are of predomin-
antly low socio-economic status (SES).
Methods
Participants
Ninety male and female PLWH were enrolled in a com-
munity program targeting individuals of low SES called
“Healthy Living for Better Days” through referrals from
the Adult Special Immunology Clinic at University of
Miami Miller School of Medicine/Jackson Health System
and other local HIV clinics. Program eligibility criteria
included: (1) confirmed HIV infection as established by
external laboratory reports, (2) men or women ≥18 years
of age, and (3) ability to attend weekly exercise sessions
at the UHealth Fitness and Wellness Center at the
University of Miami Miller School of Medicine. Program
exclusion criteria included: (1) any medical condition or
situation for which exercise would be contraindicated
and (2) pregnancy in women. The program was approved
by the Institutional Review Board for human subjects
research of the University of Miami. All participants
signed informed consent and HIPAA forms before com-
mencing the program.
Design
“Healthy Living for Better Days” was a 12-month
community-based exercise training and nutrition education
program aimed to improve the cardiovascular health of
PLWH. We began recruitment in March 2013 and closed
enrollment in November 2013. The program consisted
of supervised combined aerobic and resistance exercise
conducted three times a week and nutrition education
conducted once a week. Outcome variables were mea-
sured at baseline and months three, six, and twelve, and
they included: (1) physical characteristics (body weight,
body mass index [BMI], waist circumference [WC], and
blood pressure [BP]), (2) physical fitness (estimated max-
imal oxygen consumption [VO2max] and one-repetition
maximum [1-RM] for upper and lower body strength),
(3) lipid profile (total cholesterol [T-Chol], low-density
lipoprotein cholesterol [LDL-C], very-low density lipo-
protein cholesterol [VLDL-C], HDL-C, and triglycer-
ides [TGs]), (4) non-lipid biomarkers (hemoglobin A1c
[HbA1c], fasting glucose [FG], insulin, and C-reactive
protein [CRP]), and (5) dietary intake (Block Brief Food
Frequency Questionnaire).
Physical characteristics
Anthropometric measurements were obtained by trained
investigators using standard techniques. Weight and
height were recorded to the nearest 0.1 kg and 0.1 cm,
respectively, to calculate BMI. Waist was measured in
centimeters (cm) at the narrowest circumference halfway
between the lowest rib and the iliac crest. Systolic BP
(SBP) and diastolic BP (DBP) were measured by use of
an automatic oscillometric device, Omron BP monitor.
Three readings were made with the subjects seated after
they had rested for 5 minutes. The average of the second
and third readings was used in the analysis [14].
Physical fitness
Cardiorespiratory fitness was measured using a Rockport
One-Mile Fitness Walking Test [14]. The test was modi-
fied for use indoors at the UHealth Fitness and Wellness
Center with participants performing the one-mile walk
on a treadmill rather than on an outdoor track as
quickly as possible, and they were allowed to modify the
speed (mph) at their discretion throughout the test.
Heart rate was measured for ten seconds immediately
upon completion by palpating the radial artery. Age,
gender, body weight, and walk time were also recorded
and used in a regression equation to estimate VO2max.
Muscular strength was measured using the American
College of Sports Medicine’s protocol for 1-RM testing
[14]. Program participants completed a maximum of
four trials of 10, 8, 6, and 3 repetitions with rest periods
between 2 and 4 minutes between trials. The initial weight
was selected within the subject’s perceived capacity (50-70%
of capacity), and resistance was progressively increased
until the participants reached their maximum. The final
maximum weight lifted successfully one time for bench
press (upper body muscular strength) and leg press (lower
body muscular strength) was recorded as the 1-RM.
Blood sampling
Participants were instructed to arrive between 9:00 AM
and 10:00 AM in a fasted state for blood sampling.
Chemistry and immunoassays were performed by an
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automated analyzer (Roche Cobas-6000; Roche Diagnos-
tics, Indianapolis, IN) utilizing the manufacturer’s reagents
and following the manufacturer’s instructions. Total
cholesterol and TGs were determined in serum or plasma
by enzymatic, colorimetric assays. Intra-assay and inter-
assay coefficients of variation (CVs) were 0.7% and 1.8%,
respectively, for T-Chol and 0.9% and 2.3%, respectively,
for TGs. High-density lipoprotein cholesterol was mea-
sured using a third generation homogenous enzymatic
colorimetric assay, and the intra-assay and inter-assay CVs
were 0.6% and 1.9%, respectively. Low-density lipoprotein
cholesterol was calculated using the Friedewald equation.
Fasting glucose was measured by the hexokinase method
with intra-assay and inter-assay CVs as 1.9% and 2.7%,
respectively. C-reactive protein was quantified in serum
by a high sensitivity latex-particle enhanced immunoturbi-
dimetric assay with a detection limit of 0.1 mg/L with an
intra-assay CV of 1.1% and inter-assay CV of 2.2%.
Hemoglobin A1c in whole blood was measured by high-
performance liquid chromatography using a fully auto-
mated analyzer (Variant II Hemoglobin Testing System,
BioRad, Richmond CA), and intra-assay and inter-assay
CVs were 1.7% and 2.0%, respectively.
Questionnaires
The Block Brief Food Frequency Questionnaire is a diet-
ary assessment tool containing 55 questions, and it takes
20–35 minutes to self-administer [15]. The question-
naire obtains both frequency and quantity of food intake.
The analysis estimates daily intake of: total calories (kcal),
protein (g), total fat (g), saturated fat (g), trans fat (g),
carbohydrate (g), total sugar (including naturally occurring
sugar and added sugar) (g), added sugar (sugar and syrup
added to food and beverages during processing and
preparation (g), fiber (g), fruit intake (cup equivalent),
vegetable intake (cup equivalent), average daily glycemic
load (GL; g), and average daily glycemic index (GI).
Additional lifestyle data were obtained, which included
self-reported daily smoking (none or less than a half pack,
a half to one pack, and more than one pack), coffee
consumption (none or average cups per day), alcohol
consumption (none or average drinks per week), and
average sleep hours per night. Data were also collected
for lipid-lowering, antihypertensive, and diabetes drugs,
current ART, and missed days of taking ART in the
previous 90 days or since the last assessment.
Metabolic syndrome
Metabolic syndrome was defined using ATPIII criteria
[1]. Three or more criteria had to be met for defining
MetS: (1) fasting serum TGs (≥150 mg/dl), (2) abnormal
WC (>102 cm for men and >88 cm for women), (3) low
HDL-C level (<40 mg/dl for men and <50 mg/dl for
women), (4) high BP (≥130/85 mm Hg), or (5) high FG
level (≥110 mg/dl). Participants who reported being di-
agnosed with diabetes or who were receiving treatment
for diabetes were classified as having a high FG level.
The same criterion was used for high BP.
Statistical analyses
Metabolic syndrome was examined in relation to stand-
ard and other risk factors. Frequency and descriptive
statistics were calculated on all variables. Student’s t test
was used to assess differences between two means, and
chi square was used to examine the degree of association
of categorical variables. Variables demonstrating a signifi-
cant univariate relationship with MetS were included in a
logistic regression to assess their independent effect on
MetS diagnosis. The following variables were included in
the multivariate analysis: protease inhibitors (PIs) use,
HbA1c, FG, and the consumption of total carbohydrates,
sugar, and added sugar. SPSS 22 for Windows (IBM, Inc.,
Chicago, IL) was used for statistical analyses, and α < 0.05
was considered significant.
Results
One participant not receiving ART was excluded, leaving
89 PLWH (mean age 48 ± 7 years; mean duration of HIV
infection 17 ± 12 years; 47% men; and 66% African-
American, 22% Hispanic, and 10% non-Hispanic white)
with available data on criteria of MetS at baseline for the
final analysis. More than three-quarters (83%) of our par-
ticipants were not employed at the time of enrollment.
Seven (8%) individuals had no features of MetS. One
feature was seen in 28 (32%) individuals, two in 25 (28%),
three in 19 (21%), four in 8 (9%), and all five in 2 (2%) indi-
viduals. Thus, one in three (33%; 12 men and 17 women)
PLWH met ATPIII criteria for MetS. In our cohort, MetS
was driven by high WC and elevated BP (Table 1).
Participants with and without MetS were of similar
age and duration of HIV infection. We did not observe
any differences in the incidence of MetS based on sex,
ethnicity, or employment status.
Table 1 Individual features of MetS of study participants
Variables Overall MetS No MetS
n (%) 89 29 (33) 60
Waist circumference >102 cm
in men and >88 cm in women
63 (71) 28 (97) 35 (58)
Blood pressure ≥130/85 mm Hg (or
use of antihypertensive medication)
46 (52) 25 (86) 6 (10)
Triglycerides ≥150 mg/dl 19 (21) 14 (48) 5 (8)
Glucose ≥110 mg/dl (or use
of anti-diabetic medication)
19 (21) 9 (31) 7 (12)
HDL-C <40 mg/dl in men
and <50 mg/dl in women
13 (15) 10 (35) 2 (3)
Data are n (%). MetS metabolic syndrome, HDL-C high-density lipoprotein
cholesterol.
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The use of PIs was significantly higher among the
participants with MetS (Table 2). According to ATPIII
criteria, one in two individuals (48%) taking PIs had
MetS, while among 36 participants not receiving PIs,
only one of six individuals (17%) had MetS (p = 0.003).
Blood pressure, one of the features of MetS, was expect-
edly higher (+9% for both SBP and DBP) in those with
MetS than in those without it. The same finding explains
the higher use of antihypertensive medication among the
participants with MetS, compared to those without MetS
(43% vs. 18%, p = 0.02).
Although not statistically significant, MetS was associated
with less favorable physical characteristics and physical
fitness levels. Participants with MetS, compared to the ones
without MetS, had greater BMI (31.8 vs. 31.0, p = 0.64)
and WC (108 cm vs. 105 cm, p = 0.46) and lower esti-
mated cardiorespiratory fitness (26.5 ml/kg/min vs.
27.3 ml/kg/min, p = 0.76) and strength levels (upper
body: 112 lbs vs. 117 lbs, p = 0.69 and lower body: 209
lbs vs. 232 lbs, p = 0.24).
All biochemical markers of CVD risk (Table 3) were
less favorable among the participants with MetS. The
greatest difference between the ones with MetS and
those without MetS was observed for HDL-C (46 vs.
53 mg/dl; p = 0.07). Similarly, all biochemical markers of
diabetes (Table 3) were less favorable in the MetS group,
with HbA1c being significantly higher in the same group
compared to those without MetS (6.4 vs. 5.7%, p = 0.03;
Table 3). Self-reported use of diabetes medication was
more prevalent in those with MetS (25% vs. 6%, p = 0.01).
Daily dietary behavior (Table 4) reveals significantly
higher total energy intake among the participants with
MetS, compared to those without it (+27%, +634 Kcal,
p = 0.05). The higher energy intake in the MetS group
comes from the disparity in carbohydrates (+30%, +348
Kcal, p = 0.01), as the only macronutrient significantly
different between the groups, while fat (+24%, +176 Kcal,
p = 0.10) and protein (+24%, +92 Kcal, p = 0.08) were mar-
ginally different. Participants with MetS reported signifi-
cantly higher daily consumption of sugar (+38%, +228
Kcal, p = 0.008) and sugar in the forms of sugar and syrup
added to food and beverages (+40%, +180 Kcal, p = 0.007).
The intake of fruit, vegetables, and fiber was lower than
the national recommendations in both groups. Even
though the MetS group had slightly higher intake of
these food groups and nutrients, we did not observe a
Table 2 Characteristics of study participants with and
without MetS
MetS(n = 29) No MetS(n = 60) P value
Age (years) 49 ± 4 48 ± 8 0.54
Sex (%)
Male 12 (41) 29 (48) 0.35
Female 17 (59) 31 (52)
Duration of HIV (years) 17 ± 7 18 ± 15 0.32
ART (%)
PI 22 (78) 24 (44) 0.003
Non-PI 6 (21) 30 (55)
Ethnicity (%) 0.41
Non-Hispanic White 1 (3) 9 (15)
African-American 22 (76) 36 (60)
Hispanic 6 (21) 15 (25)
Employment (%) 0.11
Unemployed 26 (93) 48 (80)
Employed (part or full time) 2 (7) 12 (20)
Systolic BP (mmHg) 132 ± 13 122 ± 10 0.000
Diastolic BP (mmHg) 84 ± 9 78 ± 8 0.002
Body mass index (kg/m2) 31.8 ± 7.0 31.0 ± 8.2 0.64
Waist circumference (cm) 108 ± 15.0 105 ± 20 0.46
Waist-hip ratio 0.93 ± 0.07 0.92 ± 0.07 0.38
VO2max (ml/kg/min) 26.5 ± 7.7 27.3 ± 8.4 0.76
1-RM upper body (lbs) 112 ± 49 117 ± 53 0.69
1-RM lower body (lbs) 209 ± 93 232 ± 71 0.24
Current coffee drinker (%) 20 (77) 47 (78) 0.34
Current alcohol drinker (%) 6 (21) 16 (27) 0.54
Current smoker (%) 9 (31) 23 (38) 0.50
Sleep (hours) 6.5 ± 1.7 7 ± 1.8 0.70
Data are means ± SD or n (%).
MetS metabolic syndrome, ART antiretroviral therapy, PI protease inhibitors,
BP blood pressure, VO2max maximal oxygen consumption, 1-RM one
repetition maximum.
Table 3 Cardiovascular and diabetes biochemical markers
in PLWH with and without MetS
MetS(n = 29) No MetS(n = 60) P value
T-Chol (mg/dl) 184 ± 41 182 ± 36 0.83
LDL-C (mg/dl) 110 ± 31 107.34 0.71
HDL-C (mg/dl) 46 ± 15 53 ± 15 0.07
VLDL-C (mg/dl) 28 ± 17 22 ± 12 0.12
Non-HDL-C (mg/dl) 138 ± 35 130 ± 38 0.32
Total/HDL-C 4.2 ± 1.1 3.7 ± 1.3 0.09
TGs (mg/dl) 139 ± 84 112 ± 56 0.13
CRP (mg/L) 6.5 ± 8.3 5.3 ± 7.3 0.52
FG (mg/dl) 103 ± 51 91 ± 10 0.21
HbA1C (%; mmol/mol)* 6.4;46 5.7;39 0.03
Insulin (μU/mL) 17.3 ± 13.1 13.4 ± 7.6 0.15
Insulin resistance (HOMA) 4.3 ± 3.4 3.0 ± 1.9 0.09
Data are means ± SD. *SDs for HbA1C are 1.7 (MetS) and 0.6 (No MetS).
PLWH people living with HIV, MetS metabolic syndrome, T-Chol total
cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density
lipoprotein cholesterol, VLDL-C very-low density lipoprotein cholesterol,
TGs triglycerides, CRP C-reactive protein, FG fasting glucose, HbA1C
hemoglobin A1C, HOMA homeostasis model assessment.
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significant difference between the groups. Self-reported
coffee, alcohol, and smoking consumption and the
amount of daily sleep also did not differ between the
groups.
We conducted a multivariate logistic regression to
determine which of the aforementioned significant vari-
ables (PIs, HbA1c, total sugar, added sugar, and GL)
would predict the occurrence of MetS. The overall
model was significant, as X2(2) = 18.8, p < 0.001, −2 Log
Likelihood = 83.53, Nagalkerke R2 = 0.29, and 75% of the
cases were predicted correctly. A 2.4 unit increase in
HbA1c resulted in a greater likelihood of the presence of
MetS (95% confidence interval [CI]: 1.2, 4.9, p = 0.02).
While total sugar was significant (p = 0.01), the odds
ratios of just 1.01 showed little change in this variable
predicting the presence of MetS (95% CI: 1.0, 1.1).
Discussion
Our cross-sectional analysis is part of a longitudinal pro-
gram involving PLWH of predominantly low SES. Using
ATPIII criteria, 33% of PLWH taking ART were estimated
to have MetS at the time of their enrollment into “Healthy
Living for Better Days,” an exercise training and nutrition
education community program. The presence of MetS in
almost one in three individuals was driven by a high rate
of abdominal obesity and hypertension. Higher use of PIs,
elevated BP and HbA1c, greater self-reported daily caloric
intake and consumption of carbohydrates, sugar, and
added sugar, and higher GL were recorded among the
individuals with MetS, compared to those without it.
Elevated HbA1c and high total sugar consumption were
the strongest predictors and accounted for 30% of the
occurrence of MetS.
Different definitions of MetS have been utilized to
examine its incidence, and most studies have reported a
rate of 11% to 26% among PLWH. The same rates have
been comparable or slightly less in HIV-negative indi-
viduals. For example, the incidence of MetS in the
NHANES dataset among adults 20 years of age and
older was estimated to be 23% [3]. Overall, our PLWH
cohort of 20 years of age and older had higher rates of
MetS than previously reported in the general population.
However, most of our participants were 40 to 59 years old,
and their age-specific incidence of MetS was similar to the
NHANES cohort (37% vs. 41% for males and 37% vs. 37%
for females) [16]. It is still unclear if HIV infection per
se or ART use has a dominant mechanistic role in the
development of MetS. Similarly to one cohort from the
northeastern US, we found no association between dur-
ation of HIV infection and MetS [7], while the information
on duration of ART use among our participants was not
available at baseline. However, it is worth noting that all of
our subjects were receiving ART, with the overall preva-
lence of MetS in our cohort being higher than in other
PLWH cohorts. The same rate is comparable (from 31% to
45%) to three younger PLWH Italian cohorts, where all
study participants also had ART exposure [10-12].
The characteristics of MetS have been reported to differ
between PLWH and the general population, and these dif-
ferences could be attributed to HIV and/or its associated
therapies. The most commonly achieved metabolic criteria
for MetS in PLWH were hypertriglyceridemia and low
HDL-C, while the least common criterion was increased
WC [13]. The opposite was true for our cohort. The rates
of hypertriglyceridemia and low HDL-C were among the
lowest in our study. In regard to increased WC, HIV-
associated lipoatrophy and loss of abdominal subcutane-
ous fat can actually lead to lower rates of central obesity
[13]. Nonetheless, overall three out of four individuals and
almost all individuals with MetS had high WC, making
this trait the most common metabolic abnormality among
our participants. The second most prevalent component
of MetS in our study was hypertension. No specific ART
has been associated with elevated BP, and underlying fac-
tors associated with hypertension, similar to the general
population, are BMI and age [13]. The higher rate of
obesity in our cohort could explain the increased rate of
hypertension, both compared to the general population.
Our findings are similar to the NHANES dataset [3],
where the rates of abdominal obesity and hypertension, in
addition to low HDL-C, were the most common features
contributing to MetS. Therefore, we conclude that the
overall incidence of MetS and the rates of its individual
traits in our PLWH cohort resemble more the general
population, rather than other PLWH cohorts.
Table 4 Nutrient intake in PLWH with and without MetS
MetS
(n = 29)
No MetS
(n = 60)
P value
Total calories 2359 ± 1470 1725 ± 1043 0.05
Fat (g) 92 ± 65 (31) 70 ± 43 (32) 0.1
Saturated fat (g) 31 ± 23 (11) 23 ± 14 (11) 0.09
Trans fat (g) 7 ± 8 6 ± 7 0.49
Protein (g) 95 ± 61 (16) 72 ± 40 (17) 0.08
Carbohydrates (g) 291 ± 145 (49) 204 ± 136 (47) 0.01
Sugar (g) 151 ± 97 (26) 94 ± 68 (22) 0.008
Added sugar (g) 112 ± 89 67 ± 62 0.007
Servings of fruit (cups) 1.5 ± 1.08 1.2 ± 1.0 0.17
Servings of vegetables (cups) 1.6 ± 1.2 1.3 ± 1.0 0.31
Serving of fruit/vegetables (cups) 3.1 ± 2.0 2.5 ± 1.7 0.17
Fiber (g) 14 ± 10 11 ± 7 0.08
Glycemic load (g) 142 ± 87 100 ± 68 0.02
Glycemic index 52 ± 5 52 ± 4 0.66
Data are means ± SD (% of total calories).
PLWH people living with HIV, MetS metabolic syndrome.
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Specific ART medications are known to affect individual
components of MetS, and PI use is independently associ-
ated with metabolic abnormalities [17]. Protease inhibitors,
a class of ART, are hypothesized to cause peripheral lipody-
strophy, a syndrome that can lead to central fat accumula-
tion, hyperlipidemia, and insulin resistance [18]. In our
analysis, PI exposure was not an independent risk factor
for MetS, but we did observe a higher prevalence of MetS
and less favorable lipid and glucose profiles among the
participants taking PIs, compared to the ones on non-PI
based ART.
Of all lipid and non-lipid markers of CVD, the greatest
difference, with a moderate trend toward significance,
was observed for HDL-C. The individuals without MetS
had on average 7 mg/dl higher HDL-C, compared to those
with MetS. Knowing that for every 1 mg/dl increase in
HDL-C, CVD risk is reduced by 2-3% [19], this near stat-
istical significance should not be ignored as potentially
clinically relevant. It is also worth noting that none of our
participants received nevirapine, a non-nucleoside reverse
transcriptase inhibitor drug known to increase HDL-C
levels [20].
The American Diabetes Association (ADA) has recently
recommended the use of HbA1c as one of the diagnostic
tests for type 2 diabetes and also suggests a range of 5.7%
to 6.4% as a category of increased risk for diabetes (i.e.,
pre-diabetes) [21]. Additionally, most epidemiological
studies have shown that HbA1c, unlike FG, is an inde-
pendent risk factor for CVD [21,22]. According to the
ADA standards, the overall average HbA1c levels for
both of our groups (5.7% and 6.7%) can be identified as
pre-diabetes risk, while the MetS group, compared to
those without MetS, may even possess a greater risk for
cardiometabolic abnormalities. Hemoglobin A1c has rarely
been examined in PLWH in relation to MetS, while in our
cohort and among all traditional risk factors, including FG
and homeostasis model assessment, it represents the stron-
gest predictor for MetS. Thus, our findings suggest that
HbA1c might be a useful diagnostic criterion for MetS in
this patient population.
Many factors, such as a sedentary lifestyle and exces-
sive caloric intake, contribute to the incidence of MetS
[23]. We did not observe any differences between the
groups on anthropometric measurements and levels of
physical fitness, while caloric intake and four variables
related to carbohydrate consumption (total carbohydrate,
total sugar, added sugar, and GL) significantly differed
between the groups. Total carbohydrate intake and GL
have been associated with MetS in the general population
[24,25], while (added) sugars have been linked with
decreased intake of essential micronutrients [26] and are
hypothesized to contribute to weight gain [27]. For a simi-
lar body size, individuals with MetS consumed on average
more than 600 calories per day, than those without MetS.
A significant portion of excessive caloric intake in the
MetS group came from carbohydrates and more specif-
ically from the combination of naturally occurring sugar
and added artificial sugar to food and beverages. A World
Health Organization report from 2002 recommended that
sugars be limited to less than 10% of total energy per day.
Their new draft guidelines are proposing a reduction to
below 5% of total daily energy intake for additional bene-
fits [28]. The average intake of sugar for both of our
groups is substantially greater (>20% of total daily energy
intake) than the recommendations, contributing together
with high levels of HbA1c, to the presence of MetS. Add-
itionally, the Dietary Guidelines for Americans recommend
limiting total intake of discretionary calories, including
both added sugar and solid fats, to 5%-15% per day [29]. In
our study, both groups consumed added sugar alone more
than the recommended range for added sugar and solid
fats combined. More specifically, the individuals with MetS
consumed approximately 19% (equivalent to approximately
27 teaspoons) of daily calories from added sugar, compared
to 15% (16 teaspoons) among the ones without MetS. In
summary, our study indicates that unhealthy dietary habits
consisting of higher intake of carbohydrates in the form
of sugars and resulting in chronic hyperglycemia may
contribute to a higher rate of MetS in our cohort.
Lastly, our program participants were of predominantly
low SES, and two-thirds reported having only completed
high school or less, earning less than $15,000 per year, and
even more were unemployed. Low SES has been inde-
pendently associated with chronic conditions and diseases
including MetS [30], but the same finding was not
observed in our cohort. However, due to a small number
of our participants with an average or above average
income, these results should be interpreted with caution.
Future studies should explore the potential influence of
(low) SES on MetS among PLWH.
Strengths of the current study included a program
population with extensive information obtained on meta-
bolic risk factors, including physical fitness levels and
dietary habits as lifestyle characteristics highly associ-
ated with MetS. Additionally, selecting a population of
PLWH who are predominantly minority and low SES
provided an opportunity for them to participate in health-
promotion activities not typically available as part of their
conventional treatment plan. Whereas several other pro-
tocols utilized a 6–8 hour fast before blood sampling,
which could overestimate TGs and MetS rates, we utilized
a 12-hour fast, thus avoiding exaggerated TGs and ensur-
ing that serum chylomicrons would be eliminated. If par-
ticipants consumed any solid or liquid calories on the
morning of blood draw, they were re-scheduled for the
following day and told to adhere to the 12-hour fast.
Our results are hindered by several limitations. Our
study design is observational and cross-sectional, which
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precludes causality between changes in risk factors and
the rate of MetS. All of our investigators were equally
trained in performing assessments. Regardless, it was
not expected that all measurements (e.g., WC and BP)
would always be conducted in a uniform manner. We
utilized the Omron automatic oscillometric device and
not a mercury sphygmomanometer, the gold standard in
obtaining BP. Nonetheless, a recent study reported a high
correlation between Omron and mercury measurements
(SBP: r = 0.92 and DBP: r = 0.79) and low mean between-
device differences (SBP: −1.6 mmHg and DBP: −0.6 mmHg,
p < 0.05 for both) [31]. The same study reported that
Omron underestimates high BP, which could only result
in lower overall estimates of MetS in our analysis. In our
research, dietary assessment was based on a short instru-
ment and as such more prone to error in its estimate of
true dietary intake. Lastly, we did not obtain HIV RNA
levels, CD4 cell counts, and the duration of exposure to
ART to further examine the association between HIV
specific risk factors and MetS in our cohort.
Conclusions
In conclusion, the overall prevalence of MetS in our
PLWH cohort receiving ART and of predominantly low
SES is higher than previously reported in the general
population and in other PLWH cohorts. Metabolic syn-
drome as currently described does not have a common
underlying pathology. Besides genetic and environmental
factors, the complexity of MetS pathology among PLWH
additionally includes HIV infection, specific drugs, clas-
ses of drugs, and their associated adverse effects. Our
study also shows that HbA1c has the highest association
with MetS in this patient population. Furthermore, PLWH
consuming greater amount of carbohydrates in the form
of sugars could be more at risk for MetS. Further studies
are needed to examine the relationship between risk fac-
tors and prevalence of MetS over time. Assessing physical
activity and physical fitness levels and dietary habits, often
omitted in the typical analysis related to HIV and MetS,
should be included in future work to elucidate whether
MetS is a more disease dependent or lifestyle dependent
constellation of symptoms in PLWH.
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